The inventions described herein relates to devices and methods of delivering calibration or control information to a device, such as an analyte monitor.
In this specification where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date, publicly available, known to the public, part of common general knowledge, or otherwise constitutes prior art under the applicable statutory provisions; or is known to be relevant to an attempt to solve any problem with which this specification is concerned.
Currently, analyte monitoring devices, such as blood glucose monitors, include a method of executing a “control fluid” test to determine if the device is functioning according to the manufacturer's expectations. Typically, users complete a “control” test by dispensing a variable amount of fluid onto a test strip from a vial packaged with the test kit. This vial contains a fluid within a known analyte concentration. After the users dispense the fluid onto the test strip the analyte monitor assumes the fluid is a body fluid and provides a result as usual. The device and/or the user can compare the concentration of target analyte measured by the device with the known concentration contained in the control solution as a measure of the accuracy of the monitoring device.
Current systems require the user to dispense the calibration fluid from a vial containing several doses of calibration fluid. When dispensing the fluid the user must take care not to spill the fluid on the device, or on the testing surface. Completing a control test also requires that users have the dexterity to deliver a small droplet of control solution from a vial onto the test strip; this is especially difficult when diseases such as diabetes affect the patient's vision and tactile sensation.
A typical calibration or control test requires the following steps:
Currently many users of analyte monitors find executing a control test to be a burdensome experience that they often ignore. By ignoring the control test users often will acquire erroneous information from their monitors, and this information may then be used to adjust drug treatments. The use of inaccurate information can lead to serious consequesnces, such as hypoglycemia in diabetes patients from a dosage of insulin that is too high.
While certain aspects of conventional technologies have been discussed to facilitate disclosure of the invention, Applicants in no way disclaim these technical aspects, and it is contemplated that the claimed invention may encompass or include one or more of the conventional technical aspects discussed herein.
As used herein, “body fluid” encompasses whole blood, interstitial fluid, and mixtures thereof.
As used herein “integrated device” or “integrated meter” means a device or meter that includes all components necessary to perform sampling of body fluid, transport of body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid. Exemplary integrated meters are described in: U.S. Pat. Nos. 6,540,675 and 7,004,928; U.S. Patent Application Publication Nos. US 2008/0077048, US 2007/0179404, US 2007/0083131, US 2007/0179405, US 2007/0078358, and US 2007/0078313. The entire contents of each of the above-listed documents are incorporated herein by reference.
As used herein, “control material” means a material having a known and/or predetermined quantity or concentration of at least one, and possibly a plurality of, analyte(s) contained therein. The material can possess any suitable form. For example, the control material can be in the form of a liquid, a solid, a granular solid, a gas, a gel, a solution, a suspension, or any combination thereof. The analyte can comprise any suitable analyte. For example, the analyte can comprise one or more of: glucose, bilirubin, alcohol, controlled substances, toxins, hormones, and/or proteins.
It is to be understood that reference herein to first, second, third and fourth components (etc.) does not limit the present invention to embodiments where each of these components is physically separable from one another. For example, a single physical element of the invention may perform the functions of more than one of the claimed first, second, third or fourth components. Conversely, a plurality of separate physical elements working together may perform the functions of one of the claimed first, second, third or fourth components. Similarly, reference to first, second (etc.) method steps does not limit the invention to only separate steps. According to the invention, a single method step may satisfy multiple steps described herein. Conversely, a plurality of method steps could, in combination, constitute a single method step recited herein. In addition, the steps of the method are not necessarily limited to the order in which they are described or claimed herein.
It should also be understood that references herein to “the invention,” or similar language, is used to enhance readability and for convenience only, and should not be interpreted as a limitation on what is contemplated and comprehended by this disclosure and the appended claims. Instead “the invention” is intended to be interpreted as encompassing the full scope of what is claimed, regardless of the characterizations of the specific exemplary and non-limiting embodiments described in the specification.
The present invention may address one or more of the problems and deficiencies of the prior art discussed above. However, it is contemplated that the invention may prove useful in addressing other problems and deficiencies, or provides benefits and advantages, in a number of technical areas. Therefore the claimed invention should not necessarily be construed as being limited to addressing any of the particular problems or deficiencies discussed herein.
The invention can be useful with any device, but is particularly applicable to analyte monitors used in a home or clinical setting such as glucose monitors. The invention provides users of such monitors with a device that allows them to quickly and easily deliver one or more doses of calibration or control information to one or more devices, such as an analyte monitor. The invention also provides for mechanisms and methods that can automatically differentiate a calibration test from a typical test. This invention is aimed at devices requiring calibration or the ability to execute a control test. For example, in the case of analyte monitors where an analyte of a known concentration is delivered to the analyte monitor to ensure that it is functioning properly. According to the principles of the present invention, a typical user can easily and quickly execute a proper calibration test to ensure device functionality without assistance from a trained health care professional. Alternatively, the present invention can also be utilized by medical professionals in a clinical setting.
The invention can be used with an integrated device or integrated meter of the type defined above. However, the invention is not limited to use with fully integrated meters, and benefits can also be attained by use with conventional (non-integrated) meters and other diagnostic devices where collection of accurate data and analysis of data is important.
The invention can provide a device containing a single dosage, or multiple doses of control material in a convenient easy-to-use package. The control material can be contained within an applicator that is large enough for easy handling and sealed according to a number of alternative ways so that the risk of spillage or damage to the analyte monitor is greatly reduced.
This device simplifies a control test and encourages users to perform a control test more often so that any problems with their analyte monitors can be found more quickly.
The invention can provide for use of one or more dosage(s) of a predefined volume of control material, thereby ensuring more accurate data by allowing users to deliver the required amount of control solution, unlike previous methods in which it is quite possible that users could deliver too much or too little control solution. As previously mentioned, by sealing each dosage individually the viability of the control sample can be enhanced and users are less likely to use expired control material. The accuracy of the average data stored within the analyte monitor can also be increased by automatically marking or differentiating a control test from a normal or actual test so that the control test value can not impact the averages of normal analyte testing (weekly, monthly, etc) stored within the unit.
According to certain aspects, the invention provides mechanisms and methods that can determine automatically if the sampled material is body fluid or control material without the user's intervention. Also, the individual packaging of each control test ensures that each solution dosage will remain enclosed in a protective environment and allows for an extended expiration date.
According to a first aspect, the present invention provides a device comprising: a first portion configured to be grasped by the hand of the user; and a second portion defining a reservoir containing a first control material, wherein the control material comprises a target analyte of a known or predetermined concentration.
According to another aspect, the present invention provides in combination, an integrated meter comprising a housing with an opening formed therein, and the device as described above, the second portion comprising a body and a flange shaped and configured to be received by the integrated meter.
According to an additional aspect, the present invention provides a method of conveying a control material to an analyte monitor, the method comprising: (i) providing a dispenser comprising a first portion configured to be grasped by the hand of the user, and a second portion defining a reservoir having a frangible seal thereon, the reservoir containing a control material, wherein the control material contains a target analyte in a known and/or predetermined concentration; (ii) breaking the frangible seal; and (iii) conveying the control material to a location for analysis by the analyte monitor.
According to another aspect, the present invention provides a method of verifying the accuracy of the operation of an analyte monitoring device using a control material having a known and/or predetermined concentration of at least one analyte, the method comprising: providing a single or multi-test cartridge having information associated therewith defining an acceptable range of measured analyte concentration values for the control material; associating the single or multi-test cartridge with the device; reading the information off the single or multi-test cartridge; introducing a control material to the single or multi-test cartridge; the device automatically determining the presence of a control material; analyzing the control material to measure the concentration of analyte contained therein; and comparing the measured concentration with the control information to determine if the measured concentration corresponds to the acceptable range of concentration values obtained from the information.
The following description of exemplary embodiments can be read in connection with the accompanying drawings in which like numerals designate like elements and in which:
In general terms this invention describes a device that allows a user to deliver a one or more doses of control material, such as a control fluid or control solution, to one or more devices such as a meter or monitor, for example, an integrated blood glucose monitor previously described herein. The method of and apparatus for delivery of the control solution can take many forms, such as a prepackaged “blister” of control solution or a “wand,” with a known predetermined volume of control solution available for delivery to the analyte monitor. Exemplary, non-limiting embodiments of the present invention are illustrated in Figures which follow.
As illustrated in
The second portion 14 provides a mechanism for carrying a control or calibration material, as well as optionally mating with a meter or monitor (see, e.g.
The reservoir 16 containing the control material 18 can be provided with a closure or seal 20. The closure or seal 20 acts to contain the control material 18 within the reservoir 16, and to prevent contamination by shielding the control material 18 from the environment. The closure or seal 20 can be provided in any suitable form, and can be constructed of any suitable material. According to one non-limiting example, the closure or seal 20 can be in the form of a thin, frangible, closure, such as a metallic foil.
As noted above, according to one optional embodiment, the second portion 14 serves to mate with an analyte monitor such that the control material 18 can be dispensed. Thus, the second portion can be provided with a shape and size that renders it suitable for mating with a meter or monitor. It should be evident that the construction of the particular device with which the second portion 14 will mate can influence both the size and shape of the second portion 14. According to the nonlimiting illustrated example, the second portion 14 comprises a flanged 22 cylindrical body 24, as perhaps best seen in
A device constructed according to further alternative embodiments of the present invention is depicted in
As illustrated in
According to the illustrated embodiment, the first portion 112 comprises a flattened relatively wide paddle-like shape. The paddle-like shape includes facing surfaces 113 which are contoured in an hourglass type manner such that the second portion 112 is provided with a cross-section that is relatively thin toward the middle, and wider towards its ends (
The second portion 114 of the device 100 defines a reservoir 116, which houses a control material 118, which can take any suitable form, such as that described in connection with the previous embodiments. The reservoir 116 can be sealed by a corresponding closure or seal 120. The second portion 114 further comprises a flanged 122 body 124, configured in a manner similar to that of the previously described embodiment.
In the embodiments depicted in
It should be evident that the device 100 has a configuration such that it can be utilized in a manner similar to that of the previous embodiment, as depicted in
The device of the present invention, and components thereof, can be made of any suitable material, such as, metal, wood, plastic, etc. In a preferred embodiment, the device can be made of an injection molded plastic material to simplify production and reduce costs. Similarly, in one optional embodiment, a control solution is absorbed onto a carrier layer of porous absorbent material that is placed into a reservoir in the control wand then sealed with a frangible environmental seal, such as a thin aluminum foil. It is also understood that the control material could be placed directly into the cavity in the control wand and sealed without a carrier. Instead of a wand-type delivery device of the type previously described, the control material delivery device could come in the form of a:
An example of the above-mentioned alternative control material delivery devices is illustrated in
Each individual control material delivery device 152 can be provided in any suitable form. According to the illustrated embodiment, each device 152 can comprise a body 156. The body 156 can take any suitable form. According to the illustrated embodiment, the body 156 is in the form of a strip-like member. The body 156 can be formed from any suitable material, such as a plastic, fibrous material, or composite.
Attached to the body 156 is a reservoir 158. The reservoir can be provided with any suitable construction. For example, the reservoir can be configured to mate with an opening provided in an analyte monitor or meter, for example, in the manner previously described in connection with the description of
The flange-like member 164 may also include a backing 166 which is not pierceable. Thus, for example, the backing 166 is not pierceable by a hollow needle. This construction of the backing 166 can be provided to protect the fingers of a user when the reservoir 158 is inserted into a meter or monitor, which includes a piercing element, such as a hollow needle, which is used to access the control material 160 within the reservoir 158.
Devices constructed according to further alternative embodiments of the present invention are depicted in
The devices and methods according to the embodiments depicted in
As illustrated, for example, in
According to the illustrated embodiment, the first portion 212 comprises a flattened relatively wide paddle-like shape. The paddle-like shape includes facing surfaces 213 which are contoured in an hourglass type manner such that the second portion 212 is provided with a cross-section that is relatively thin toward the middle, and wider towards its ends (
The device 200 may further include a second portion 214 with a flexible neck construction 230. The flexible neck 230 facilitates usage of the device by permitting relative movement between the first portion 212 and second portion 214 of the device. The flexible neck 230 can facilitate use of the device 200 in connection with mating the body 224 with an opening in a meter. The relative movement between the first portion 212 and the second portion 214 facilitates keeping the flanged 222 body 224 pressed flat against the opening, thus improving the ability to form a seal therewith. The flexible neck 230 may possess any suitable construction permits this desired relative movement. Thus, the flexible neck may simply comprise a relatively thin neck of flexible material, or other alternative configurations. According to the illustrated examples, the flexible neck 230 comprises a series of sections 231 interconnected by one or more thin flexible necks 232.
The second portion 214 of the device 200 can define a reservoir 216, which houses a control material 218, as described in connection with the previous embodiments. Optionally, the control material 218 can contain one or more target analytes having a known and/or predetermined concentration and can be in liquid or flowable form as illustrated in, for example,
According to certain alternative embodiments, the device 200 can include one or more features which allow the user to urge the control material out of the device so as to deliver it to its intended location. A number of such features are contemplated, including the use of positive and/or negative pressures. According to one nonlimiting, specific example, as illustrated in
As mentioned above, in the embodiments depicted in
It should be evident that the device 200 has a configuration such that it can be utilized in a manner similar to that described in connection with the previous embodiments.
The device 200 illustrated in
The device 200 illustrated in
The device 200′ illustrated in
According to further optional embodiments of the present invention, any of the previously or subsequently described embodiments can be modified so as to include an alternative reservoir construction, an example of which being illustrated in the embodiments depicted in
The above noted concepts can be executed in any suitable manner. According to the nonlimiting illustrated embodiment, the modified reservoir portion 216′ comprises a lower member 270 defining a recess 272 therein. Received within a recess 272 is a separable reservoir component 274 containing the control material 218. The separable component may be closed by a frangible seal 220, as previously described, As noted above, this separable component 274 can be formed of any suitable material, such as a LMVTR plastic material. The separable component 274 can be retained within the recess 272 in any suitable fashion. Contemplated alternatives include adhesives, fasteners, and frictional retention. According to the illustrated embodiments, the separable component 274 is retained within the recess 272 by plurality of interacting frictional detents 276, 278.
Further aspects of the invention involves analyte testing/monitoring devices and methods including the devices (e.g., 100, 200, 200′) of the type described above in conjunction with an integrated analyte monitor or meter. The integrated monitor or meter optionally being capable of one or more of the following:
To complete the described steps automatically the analyte monitor should also have the capability of gathering calibration information automatically, such as from an analyte concentration measuring and analysis mechanism contained with the device. If analysis site(s) is/are contained within a single strip or multi-test cartridge CR, as illustrated in
One advantage of the invention is automated detection and marking of a control test to distinguish that test from, for example, a test involving a sample of body fluid. This can be accomplished by several methods; one method of identifying a control test is described as follows. The control material can be designed such that it reacts with the analysis site in a manner distinguishable from the reaction with a bodily fluid. For example, the viscosity of the control material can be so different, either lower or higher than the tested body fluid, that the rate of reaction or sample delivery can be used to distinguish control material from body fluid. Specifically, glucose monitors typically have stated hematocrit ranges that are acceptable for use with the device. As hematocrit increases the viscosity of blood also increases. The analysis site and method could be designed in such a manner that the rate of reaction is inversely related to hematocrit (higher hematocrit=slower reaction). This has been described, for example, in US 2006/0281187, the entire contents of which is incorporated herein by reference. To accomplish this, the control material used within the analysis site could be contained in a porous material. The size of the pores in the material can be used to control the rate of reaction. The control fluid can be designed such that its viscosity is lower than the equivalent viscosity of the lowest allowable hematocrit level. Therefore as the analysis is completed within the integrated monitor the rate of reaction can be used to identify control material tests.
Another method of identifying a control sample versus a body fluid sample involves adding identifying markers to the control material. For example, control material could be identified by optical detection by adding color within the detection wavelength such that a color change of an order of magnitude higher than physiologically possible given the kinetics of the assay occurs nearly instantaneously. The degree of color added via a dye or other colored means is enough to detect via this method, but not so much as to reduce the dynamic detection range of the system so that the proper level of analyte detection in the control material can correctly indicate system analyte recovery status as “Pass” or “Fail” through clear audible and/or visual signals. Another similar option that may be implemented is to provide the control material with a chemical marker that initially reacts with the analysis site to produce an initial spike in color indicating to the meter the presence of control solution. The initial color spike can be designed to quickly disappear. Subsequently, the analysis site reacts with the analyte(s) in a manner that can be read and interpreted to determine the concentration thereof.
Other similar methods of observing the time rate of change of the analysis site (reagent) are also comprehended, i.e., very slow reaction, or reactions proceeding along known value vs. time plots, etc.
According to further alternative embodiments, the automated determination of a control solution test can be accomplished using algorithms executed by the electronic components within a monitor or meter.
A method performed according to the principles of one embodiment of the present invention includes one or more of the steps in FIGS. 27 and 28A-28D:\
Step 1: Provide calibration information to the monitor or device (e.g.,
Step 2: Use control material applicator (100, 200, 200′) to deliver a dose of control material to monitor or device (M) (
Step 3: Integrated monitor analyzes the control material and determines that sample is a control test as indicated by any suitable symbol, such as the “check-mark” symbol on LCD (
Step 4a: Control material is analyzed and its analyte concentration value is displayed (e.g., 100 mg/dL) and compared against stored calibration values. In this example, the value is within the expected range and device displays any suitable symbol, such as the “check” indicating “pass” (
Step 4b: Control material is analyzed, the measured analyte concentration displayed and found to be outside of the expected range. In this case, the monitor indicates a failed test by displaying any suitable symbol, such as crossed-out check mark. Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol. Note the “i” symbol indicates that user should look at manual to see how to address the failed test (
An alternative method performed according to a further optional embodiment is illustrated in FIGS. 27 and 29A-29D, and is described as follows.
Step 1: Provide calibration information to the monitor or device (e.g.,
Step 2: Use control material applicator (100, 200, 200′) to deliver a dose of control material (18, 118, 218) to monitor or device (M) (
Step 3: Integrated monitor analyzes the control material and determines that sample is a control test as indicated by any suitable symbol, such as the “check-mark” symbol on LCD (e.g.,
Step 4a: Control material is analyzed and its analyte concentration value is compared against stored calibration values. In this example, the value is within the expected range and device displays any suitable symbol, such as the “check” and a “P” indicating “pass” (
Step 4b: Control material is analyzed, the measured analyte concentration value is compared by the meter M against stored control or calibration values and found to be outside of the expected range. In this case the monitor displays a fail test. Any suitable symbol, such as the symbol indicated by the crossed check mark and “F,” indicative of a failed control test. Additional and/or alternative visual and audible signals are contemplated. For example, the meter M can play a recorded spoken “fail” message. Note the “i” symbol indicates that user should look at manual to see how to address the failed test (
It should be understood that the present invention is not limited to use of the devices (100, 200, 200′) described herein with a particular type of meter or device. The present invention contemplates devices and methods that do not rely upon an integrated type meter or monitor. For example, many commercially available blood glucose monitoring systems include a lancing device, test strips and meter, one or more of which are separate components of the system. An arrangement and a control testing method performed according to an alternative embodiment of the present invention is illustrated in
According to one optional modification of the above described embodiment of
Numbers expressing quantities of ingredients, constituents, reaction conditions, and so forth used in this specification are to be understood as being modified in all instances by the term “about”. Notwithstanding that the numerical ranges and parameters setting forth, the broad scope of the subject matter presented herein are approximations, the numerical values set forth are indicated as precisely as possible. Any numerical value, however, may inherently contain certain errors necessarily resulting from the standard deviation found in their respective measurement techniques. None of the elements recited in the appended claims should be interpreted as invoking 35 U.S.C. §112, ¶6, unless the term “means” is explicitly used.
Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention as defined in the appended claims.
The present application claims priority to U.S. patent application No. 61/358,791, filed Jun. 25, 2010, and U.S. patent application Ser. No. 61/265,247, filed Nov. 30, 2009.
Number | Name | Date | Kind |
---|---|---|---|
842690 | Oswalt | Jan 1907 | A |
D137874 | Partridge | May 1944 | S |
2749797 | Harks | Mar 1950 | A |
3092465 | Adams, Jr. | Jun 1963 | A |
3310002 | Wilburn | Mar 1967 | A |
3620209 | Kravitz | Nov 1971 | A |
3623475 | Sanz et al. | Nov 1971 | A |
3626929 | Sanz et al. | Dec 1971 | A |
3630957 | Rey | Dec 1971 | A |
D223165 | Komendat | Mar 1972 | S |
3723064 | Liotta | Mar 1973 | A |
3741197 | Sanz et al. | Jun 1973 | A |
3961898 | Neeley et al. | Jun 1976 | A |
4014328 | Cluff et al. | Mar 1977 | A |
4042335 | Clement | Aug 1977 | A |
4057394 | Genshaw | Nov 1977 | A |
4109655 | Chacornac | Aug 1978 | A |
4254083 | Columbus | Mar 1981 | A |
4258001 | Pierce et al. | Mar 1981 | A |
4260257 | Neeley et al. | Apr 1981 | A |
4289459 | Neeley et al. | Sep 1981 | A |
4311792 | Avery | Jan 1982 | A |
4321397 | Nix et al. | Mar 1982 | A |
4350762 | DeLuca et al. | Sep 1982 | A |
4394512 | Batz | Jul 1983 | A |
4414975 | Ryder et al. | Nov 1983 | A |
4416279 | Lindner et al. | Nov 1983 | A |
4418037 | Katsuyama et al. | Nov 1983 | A |
4422941 | Vaughan, Jr. et al. | Dec 1983 | A |
4429700 | Thees et al. | Feb 1984 | A |
4627445 | Garcia et al. | Dec 1986 | A |
4637403 | Garcia et al. | Jan 1987 | A |
4637406 | Guinn et al. | Jan 1987 | A |
4653513 | Dombrowski | Mar 1987 | A |
4661319 | Lape | Apr 1987 | A |
4702261 | Cornell et al. | Oct 1987 | A |
4711250 | Gilbaugh, Jr. et al. | Dec 1987 | A |
4737458 | Batz et al. | Apr 1988 | A |
4749655 | Monthony et al. | Jun 1988 | A |
4767415 | Duffy | Aug 1988 | A |
4774192 | Terminiello et al. | Sep 1988 | A |
4790979 | Terminiello et al. | Dec 1988 | A |
4794926 | Munsch et al. | Jan 1989 | A |
4815843 | Tiefenthaler et al. | Mar 1989 | A |
4829470 | Wang | May 1989 | A |
4846785 | Cassou et al. | Jul 1989 | A |
4887306 | Hwang et al. | Dec 1989 | A |
4920977 | Haynes | May 1990 | A |
4930525 | Palestrant | Jun 1990 | A |
4935346 | Phillips | Jun 1990 | A |
4953552 | De Marzo | Sep 1990 | A |
4966646 | Zdeblick | Oct 1990 | A |
4995402 | Smith | Feb 1991 | A |
5029583 | Meserol | Jul 1991 | A |
5049487 | Phillips et al. | Sep 1991 | A |
5050617 | Columbus et al. | Sep 1991 | A |
5059394 | Phillips et al. | Oct 1991 | A |
5077199 | Basagni et al. | Dec 1991 | A |
5094943 | Siedel et al. | Mar 1992 | A |
5116759 | Klainer et al. | May 1992 | A |
5131404 | Neeley et al. | Jul 1992 | A |
5141868 | Shanks et al. | Aug 1992 | A |
5145565 | Kater et al. | Sep 1992 | A |
5146437 | Boucheron | Sep 1992 | A |
5153416 | Neeley | Oct 1992 | A |
5164575 | Neeley et al. | Nov 1992 | A |
5166498 | Neeley | Nov 1992 | A |
5174291 | Schoonen et al. | Dec 1992 | A |
5176632 | Bernardi | Jan 1993 | A |
5179005 | Phillips et al. | Jan 1993 | A |
5183741 | Arai et al. | Feb 1993 | A |
5196302 | Kidwell | Mar 1993 | A |
5208163 | Charlton et al. | May 1993 | A |
5213966 | Vuorinen et al. | May 1993 | A |
5217480 | Haber et al. | Jun 1993 | A |
5218966 | Yamasawa | Jun 1993 | A |
5223219 | Subramanian et al. | Jun 1993 | A |
5234818 | Zimmermann et al. | Aug 1993 | A |
5241969 | Carson et al. | Sep 1993 | A |
5251126 | Kahn et al. | Oct 1993 | A |
D341848 | Bigelow et al. | Nov 1993 | S |
5266266 | Nason | Nov 1993 | A |
5275159 | Griebel | Jan 1994 | A |
5278079 | Gubinski et al. | Jan 1994 | A |
5288646 | Lundsgaard et al. | Feb 1994 | A |
5299571 | Mastrototaro | Apr 1994 | A |
5301686 | Newman | Apr 1994 | A |
5302513 | Miike et al. | Apr 1994 | A |
5304468 | Phillips et al. | Apr 1994 | A |
5306623 | Kiser et al. | Apr 1994 | A |
5308767 | Terashima | May 1994 | A |
5320607 | Ishibashi | Jun 1994 | A |
5354537 | Moreno | Oct 1994 | A |
5360595 | Bell et al. | Nov 1994 | A |
5368047 | Suzuki et al. | Nov 1994 | A |
5383512 | Jarvis | Jan 1995 | A |
5390671 | Lord et al. | Feb 1995 | A |
5399316 | Yamada | Mar 1995 | A |
5401110 | Neeley | Mar 1995 | A |
5402798 | Swierczek et al. | Apr 1995 | A |
5441513 | Roth | Aug 1995 | A |
5451350 | Macho et al. | Sep 1995 | A |
5458140 | Eppstein et al. | Oct 1995 | A |
5460777 | Kitajima et al. | Oct 1995 | A |
5460968 | Yoshida et al. | Oct 1995 | A |
5482473 | Lord et al. | Jan 1996 | A |
5506200 | Hirschkoff et al. | Apr 1996 | A |
5507288 | Bö{umlaut over ( )}cker et al. | Apr 1996 | A |
5508200 | Tiffany et al. | Apr 1996 | A |
5510266 | Bonner et al. | Apr 1996 | A |
5514152 | Smith | May 1996 | A |
5568806 | Cheney, II et al. | Oct 1996 | A |
5569287 | Tezuka et al. | Oct 1996 | A |
5575403 | Charlton et al. | Nov 1996 | A |
5577499 | Teves | Nov 1996 | A |
5582184 | Erickson et al. | Dec 1996 | A |
5586553 | Halili et al. | Dec 1996 | A |
5591139 | Lin et al. | Jan 1997 | A |
5611809 | Marshall et al. | Mar 1997 | A |
5624458 | Lipscher | Apr 1997 | A |
5630986 | Charlton et al. | May 1997 | A |
5632410 | Moulton et al. | May 1997 | A |
5636632 | Bommannan et al. | Jun 1997 | A |
5647851 | Pokras | Jul 1997 | A |
5658515 | Lee et al. | Aug 1997 | A |
5660791 | Brenneman et al. | Aug 1997 | A |
5676850 | Reed et al. | Oct 1997 | A |
5680858 | Hansen et al. | Oct 1997 | A |
5681484 | Zanzucchi et al. | Oct 1997 | A |
5682233 | Brinda | Oct 1997 | A |
5697901 | Eriksson | Dec 1997 | A |
5701181 | Boiarski et al. | Dec 1997 | A |
5701910 | Powles et al. | Dec 1997 | A |
5705018 | Hartley | Jan 1998 | A |
5708787 | Nakano et al. | Jan 1998 | A |
5715417 | Gardien et al. | Feb 1998 | A |
5730753 | Morita | Mar 1998 | A |
5735273 | Kurnik et al. | Apr 1998 | A |
5736103 | Pugh | Apr 1998 | A |
5741211 | Renirie et al. | Apr 1998 | A |
5746217 | Erickson et al. | May 1998 | A |
5746720 | Stouder, Jr. | May 1998 | A |
5757666 | Schreiber et al. | May 1998 | A |
5759364 | Charlton et al. | Jun 1998 | A |
5766066 | Ranniger | Jun 1998 | A |
5771890 | Tamada | Jun 1998 | A |
5797693 | Jaeger | Aug 1998 | A |
5801057 | Smart et al. | Sep 1998 | A |
5807375 | Gross et al. | Sep 1998 | A |
5820570 | Erickson et al. | Oct 1998 | A |
5827183 | Kurnik et al. | Oct 1998 | A |
5840020 | Heinonen et al. | Nov 1998 | A |
5841126 | Fossum et al. | Nov 1998 | A |
5843692 | Phillips et al. | Dec 1998 | A |
5846837 | Thym et al. | Dec 1998 | A |
5854074 | Charlton et al. | Dec 1998 | A |
D403975 | Douglas et al. | Jan 1999 | S |
5855801 | Lin et al. | Jan 1999 | A |
5856195 | Charlton et al. | Jan 1999 | A |
5858194 | Bell | Jan 1999 | A |
5866281 | Guckel et al. | Feb 1999 | A |
5871494 | Simons et al. | Feb 1999 | A |
5879310 | Sopp et al. | Mar 1999 | A |
5879326 | Godshall et al. | Mar 1999 | A |
5879367 | Latterell et al. | Mar 1999 | A |
5891053 | Sesekura | Apr 1999 | A |
5893870 | Talen et al. | Apr 1999 | A |
5911711 | Pelkey | Jun 1999 | A |
5911737 | Lee et al. | Jun 1999 | A |
5912139 | Iwata et al. | Jun 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5928207 | Pisano et al. | Jul 1999 | A |
5930873 | Wyser | Aug 1999 | A |
5938679 | Freeman et al. | Aug 1999 | A |
5945678 | Yanagisawa | Aug 1999 | A |
5951492 | Douglas et al. | Sep 1999 | A |
5951493 | Douglas et al. | Sep 1999 | A |
5954685 | Tierney | Sep 1999 | A |
5962215 | Douglas et al. | Oct 1999 | A |
5968760 | Phillips et al. | Oct 1999 | A |
5968765 | Grage et al. | Oct 1999 | A |
5971941 | Simons et al. | Oct 1999 | A |
5972294 | Smith et al. | Oct 1999 | A |
5986754 | Harding | Nov 1999 | A |
5989409 | Kurnik et al. | Nov 1999 | A |
5993189 | Mueller et al. | Nov 1999 | A |
6001067 | Shults et al. | Dec 1999 | A |
6005545 | Nishida et al. | Dec 1999 | A |
6010463 | Lauks et al. | Jan 2000 | A |
6010519 | Mawhirt et al. | Jan 2000 | A |
6014135 | Fernandes | Jan 2000 | A |
6014577 | Henning et al. | Jan 2000 | A |
6023629 | Tamada | Feb 2000 | A |
6027459 | Shain et al. | Feb 2000 | A |
6030827 | Davis et al. | Feb 2000 | A |
6032059 | Henning et al. | Feb 2000 | A |
6036924 | Simons et al. | Mar 2000 | A |
6041253 | Kost et al. | Mar 2000 | A |
6050988 | Zuck | Apr 2000 | A |
6056701 | Duchon et al. | May 2000 | A |
6056734 | Jacobsen et al. | May 2000 | A |
6058321 | Swayze et al. | May 2000 | A |
6059815 | Lee et al. | May 2000 | A |
6061128 | Zweig et al. | May 2000 | A |
6063039 | Cunningham et al. | May 2000 | A |
6071294 | Simons et al. | Jun 2000 | A |
6077660 | Wong et al. | Jun 2000 | A |
6080116 | Erickson et al. | Jun 2000 | A |
6083196 | Trautman et al. | Jul 2000 | A |
6086544 | Hibner et al. | Jul 2000 | A |
6090790 | Eriksson | Jul 2000 | A |
6091975 | Daddona et al. | Jul 2000 | A |
6093156 | Cunningham et al. | Jul 2000 | A |
6097831 | Wieck et al. | Aug 2000 | A |
6099484 | Douglas et al. | Aug 2000 | A |
6100107 | Lei et al. | Aug 2000 | A |
6102933 | Lee et al. | Aug 2000 | A |
6103033 | Say et al. | Aug 2000 | A |
6103197 | Werner | Aug 2000 | A |
6106751 | Talbot et al. | Aug 2000 | A |
6118126 | Zanzucchi | Sep 2000 | A |
6120676 | Heller et al. | Sep 2000 | A |
6123861 | Santini, Jr. et al. | Sep 2000 | A |
6126899 | Woudenberg et al. | Oct 2000 | A |
6132449 | Lum et al. | Oct 2000 | A |
6139562 | Mauze et al. | Oct 2000 | A |
6142939 | Eppstein et al. | Nov 2000 | A |
6152942 | Brenneman et al. | Nov 2000 | A |
6162639 | Douglas | Dec 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6176865 | Mauze et al. | Jan 2001 | B1 |
6183434 | Eppstein et al. | Feb 2001 | B1 |
6183489 | Douglas et al. | Feb 2001 | B1 |
6187210 | Lebouiz et al. | Feb 2001 | B1 |
6192891 | Gravel et al. | Feb 2001 | B1 |
6200296 | Dibiasi et al. | Mar 2001 | B1 |
6206841 | Cunningham et al. | Mar 2001 | B1 |
6214626 | Meller et al. | Apr 2001 | B1 |
6219574 | Cormier et al. | Apr 2001 | B1 |
6228100 | Schraga | May 2001 | B1 |
6230051 | Cormier et al. | May 2001 | B1 |
6231531 | Lum et al. | May 2001 | B1 |
6241862 | McAleer et al. | Jun 2001 | B1 |
6242207 | Douglas et al. | Jun 2001 | B1 |
6245215 | Douglas et al. | Jun 2001 | B1 |
6251083 | Yum et al. | Jun 2001 | B1 |
6251260 | Heller et al. | Jun 2001 | B1 |
6254586 | Mann et al. | Jul 2001 | B1 |
6255061 | Mori et al. | Jul 2001 | B1 |
6256533 | Yuzhakov et al. | Jul 2001 | B1 |
6268162 | Phillips et al. | Jul 2001 | B1 |
6271045 | Douglas et al. | Aug 2001 | B1 |
6272364 | Kurnik | Aug 2001 | B1 |
6283926 | Cunningham et al. | Sep 2001 | B1 |
6289230 | Chaiken et al. | Sep 2001 | B1 |
6298254 | Tamada | Oct 2001 | B2 |
6299578 | Kurnik et al. | Oct 2001 | B1 |
6309351 | Kurnik et al. | Oct 2001 | B1 |
D450711 | Istvan et al. | Nov 2001 | S |
6312612 | Sherman et al. | Nov 2001 | B1 |
6312888 | Wong et al. | Nov 2001 | B1 |
6322808 | Trautman et al. | Nov 2001 | B1 |
6329161 | Heller et al. | Dec 2001 | B1 |
6331266 | Powell et al. | Dec 2001 | B1 |
6332871 | Douglas et al. | Dec 2001 | B1 |
6334856 | Allen et al. | Jan 2002 | B1 |
6350273 | Minagawa et al. | Feb 2002 | B1 |
6352514 | Douglas et al. | Mar 2002 | B1 |
6356776 | Berner et al. | Mar 2002 | B1 |
6358265 | Thorne, Jr. et al. | Mar 2002 | B1 |
6364890 | Lum et al. | Apr 2002 | B1 |
6375626 | Allen et al. | Apr 2002 | B1 |
6375627 | Mauze et al. | Apr 2002 | B1 |
6379969 | Mauze et al. | Apr 2002 | B1 |
6391005 | Lum et al. | May 2002 | B1 |
6409679 | Pyo | Jun 2002 | B2 |
6428664 | BhulLar et al. | Aug 2002 | B1 |
6449608 | Morita et al. | Sep 2002 | B1 |
6455324 | Douglas | Sep 2002 | B1 |
6500134 | Cassone | Dec 2002 | B1 |
6520973 | McGarry | Feb 2003 | B1 |
6530892 | Kelly | Mar 2003 | B1 |
6537243 | Henning et al. | Mar 2003 | B1 |
6540675 | Aceti et al. | Apr 2003 | B2 |
6544475 | Douglas et al. | Apr 2003 | B1 |
6555061 | Leong et al. | Apr 2003 | B1 |
6558624 | Lemmon et al. | May 2003 | B1 |
6579690 | Bonnecaze et al. | Jun 2003 | B1 |
6602205 | Erickson et al. | Aug 2003 | B1 |
6612111 | Hodges et al. | Sep 2003 | B1 |
6616616 | Fritz et al. | Sep 2003 | B2 |
6626874 | Duchamp | Sep 2003 | B1 |
6656167 | Numao et al. | Dec 2003 | B2 |
6679852 | Schmelzeisen-Redeker et al. | Jan 2004 | B1 |
6706000 | Perez et al. | Mar 2004 | B2 |
6706049 | Moerman | Mar 2004 | B2 |
6706159 | Moerman et al. | Mar 2004 | B2 |
6740800 | Cunningham | May 2004 | B1 |
6748275 | Lattner et al. | Jun 2004 | B2 |
6753187 | Cizdziel et al. | Jun 2004 | B2 |
6766817 | da Silva | Jul 2004 | B2 |
6793633 | Douglas et al. | Sep 2004 | B2 |
6830669 | Miyazaki et al. | Dec 2004 | B2 |
6836678 | Tu | Dec 2004 | B2 |
6837858 | Cunningham et al. | Jan 2005 | B2 |
6847451 | Pugh | Jan 2005 | B2 |
6918404 | Dias da Silva | Jul 2005 | B2 |
6919960 | Hansen et al. | Jul 2005 | B2 |
6923764 | Aceti et al. | Aug 2005 | B2 |
6936476 | Anderson et al. | Aug 2005 | B1 |
6988996 | Roe et al. | Jan 2006 | B2 |
7004928 | Aceti et al. | Feb 2006 | B2 |
7011630 | Desai et al. | Mar 2006 | B2 |
7025774 | Freeman et al. | Apr 2006 | B2 |
7066586 | Da Silva | Jun 2006 | B2 |
7066890 | Lam et al. | Jun 2006 | B1 |
7141058 | Briggs et al. | Nov 2006 | B2 |
7156809 | Quy | Jan 2007 | B2 |
7192061 | Martin | Mar 2007 | B2 |
D540343 | Cummins | Apr 2007 | S |
7223365 | Freiherr Von Der Goltz | May 2007 | B2 |
7225008 | Ward et al. | May 2007 | B1 |
7226461 | Boecker et al. | Jun 2007 | B2 |
D551243 | Young | Sep 2007 | S |
7270970 | Anderson et al. | Sep 2007 | B2 |
7297151 | Boecker et al. | Nov 2007 | B2 |
7343188 | Sohrab | Mar 2008 | B2 |
7344507 | Briggs et al. | Mar 2008 | B2 |
7427377 | Zanzucchi et al. | Sep 2008 | B2 |
D599373 | Kobayashi et al. | Sep 2009 | S |
D601578 | Poulet et al. | Oct 2009 | S |
7682318 | Alden et al. | Mar 2010 | B2 |
7803123 | Perez et al. | Sep 2010 | B2 |
7887494 | Emery et al. | Feb 2011 | B2 |
D642191 | Barnett et al. | Jul 2011 | S |
20010001034 | Douglas | May 2001 | A1 |
20010027328 | Lum et al. | Oct 2001 | A1 |
20010053891 | Ackley | Dec 2001 | A1 |
20020002326 | Causey, III et al. | Jan 2002 | A1 |
20020002344 | Douglas et al. | Jan 2002 | A1 |
20020004640 | Conn et al. | Jan 2002 | A1 |
20020006355 | Whitson | Jan 2002 | A1 |
20020016568 | Lebel et al. | Feb 2002 | A1 |
20020020688 | Sherman et al. | Feb 2002 | A1 |
20020023852 | Mcivor et al. | Feb 2002 | A1 |
20020042594 | Lum et al. | Apr 2002 | A1 |
20020052618 | Haar et al. | May 2002 | A1 |
20020087056 | Aceti et al. | Jul 2002 | A1 |
20020136667 | Subramanian et al. | Sep 2002 | A1 |
20020137998 | Smart et al. | Sep 2002 | A1 |
20020160520 | Orloff et al. | Oct 2002 | A1 |
20020168290 | Yuzhakov et al. | Nov 2002 | A1 |
20020169394 | Eppstein et al. | Nov 2002 | A1 |
20020169411 | Sherman et al. | Nov 2002 | A1 |
20020177761 | Orloff et al. | Nov 2002 | A1 |
20020183102 | Withers et al. | Dec 2002 | A1 |
20020188223 | Perez et al. | Dec 2002 | A1 |
20020198444 | Uchigaki et al. | Dec 2002 | A1 |
20030012693 | Otillar et al. | Jan 2003 | A1 |
20030028087 | Yuzhakov et al. | Feb 2003 | A1 |
20030028125 | Yuzhakov et al. | Feb 2003 | A1 |
20030039587 | Niermann | Feb 2003 | A1 |
20030083685 | Freeman et al. | May 2003 | A1 |
20030083686 | Freeman et al. | May 2003 | A1 |
20030116596 | Terasawa | Jun 2003 | A1 |
20030135166 | Gonnelli | Jul 2003 | A1 |
20030135333 | Aceti | Jul 2003 | A1 |
20030153844 | Smith et al. | Aug 2003 | A1 |
20030153900 | Aceti et al. | Aug 2003 | A1 |
20030175987 | Verdonk et al. | Sep 2003 | A1 |
20030206302 | Pugh | Nov 2003 | A1 |
20030207441 | Eyster et al. | Nov 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030211619 | Olson et al. | Nov 2003 | A1 |
20030212344 | Yuzhakov et al. | Nov 2003 | A1 |
20030212347 | Sohrab | Nov 2003 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040030353 | Schmelzeisen-Redeker et al. | Feb 2004 | A1 |
20040049219 | Briggs et al. | Mar 2004 | A1 |
20040059256 | Perez | Mar 2004 | A1 |
20040073140 | Douglas | Apr 2004 | A1 |
20040092842 | Boecker et al. | May 2004 | A1 |
20040092995 | Boecker et al. | May 2004 | A1 |
20040096959 | Stiene et al. | May 2004 | A1 |
20040098009 | Boecker et al. | May 2004 | A1 |
20040102803 | Boecker et al. | May 2004 | A1 |
20040122339 | Roe et al. | Jun 2004 | A1 |
20040132167 | Rule et al. | Jul 2004 | A1 |
20040138588 | Saikley et al. | Jul 2004 | A1 |
20040155084 | Brown | Aug 2004 | A1 |
20040178218 | Schomakers et al. | Sep 2004 | A1 |
20040186394 | Roe et al. | Sep 2004 | A1 |
20040191119 | Zanzucchi et al. | Sep 2004 | A1 |
20040202576 | Aceti et al. | Oct 2004 | A1 |
20040209755 | Moore et al. | Oct 2004 | A1 |
20040236251 | Roe et al. | Nov 2004 | A1 |
20040238675 | Banaszkiewicz et al. | Dec 2004 | A1 |
20050010134 | Douglas et al. | Jan 2005 | A1 |
20050015020 | LeVaughn et al. | Jan 2005 | A1 |
20050096686 | Allen | May 2005 | A1 |
20050106713 | Phan et al. | May 2005 | A1 |
20050159678 | Taniike et al. | Jul 2005 | A1 |
20050187532 | Thurau et al. | Aug 2005 | A1 |
20050202567 | Zanzucchi et al. | Sep 2005 | A1 |
20050202733 | Yoshimura et al. | Sep 2005 | A1 |
20050215872 | Berner et al. | Sep 2005 | A1 |
20050215923 | Wiegel | Sep 2005 | A1 |
20050244981 | Frey et al. | Nov 2005 | A1 |
20050245844 | Mace et al. | Nov 2005 | A1 |
20050277972 | Wong et al. | Dec 2005 | A1 |
20060008389 | Sacherer et al. | Jan 2006 | A1 |
20060036134 | Tarassenko et al. | Feb 2006 | A1 |
20060117616 | Jones et al. | Jun 2006 | A1 |
20060135873 | Karo et al. | Jun 2006 | A1 |
20060155317 | List | Jul 2006 | A1 |
20060178600 | Kennedy et al. | Aug 2006 | A1 |
20060189908 | Kennedy | Aug 2006 | A1 |
20060204399 | Freeman et al. | Sep 2006 | A1 |
20060229533 | Hoenes et al. | Oct 2006 | A1 |
20060241517 | Fowler et al. | Oct 2006 | A1 |
20060257993 | Mcdevitt et al. | Nov 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20060281187 | Emery et al. | Dec 2006 | A1 |
20070017824 | Rippeth et al. | Jan 2007 | A1 |
20070078313 | Emery et al. | Apr 2007 | A1 |
20070078358 | Escutia et al. | Apr 2007 | A1 |
20070083131 | Escutia et al. | Apr 2007 | A1 |
20070149863 | Padmanabhan et al. | Jun 2007 | A1 |
20070179404 | Escutia et al. | Aug 2007 | A1 |
20070179405 | Emery et al. | Aug 2007 | A1 |
20070255181 | Alvarez-icaza et al. | Nov 2007 | A1 |
20070255302 | Koeppel et al. | Nov 2007 | A1 |
20070274869 | Rannikko | Nov 2007 | A1 |
20080046831 | Imai et al. | Feb 2008 | A1 |
20080077048 | Escutia et al. | Mar 2008 | A1 |
20080135559 | Byrd | Jun 2008 | A1 |
20080194934 | Ray et al. | Aug 2008 | A1 |
20090018426 | Markle et al. | Jan 2009 | A1 |
20090156923 | Power et al. | Jun 2009 | A1 |
20100021948 | Lipman et al. | Jan 2010 | A1 |
20100095229 | Dixon et al. | Apr 2010 | A1 |
20100185120 | Sacherer et al. | Jul 2010 | A1 |
20120166090 | Lipman et al. | Jun 2012 | A1 |
Number | Date | Country |
---|---|---|
2 513 465 | Aug 2004 | CA |
199 22 413 | Nov 2000 | DE |
103 02 501 | Aug 2004 | DE |
0 396-016 | Nov 1990 | EP |
0 396-016 | Nov 1990 | EP |
0 255-338 | Feb 1998 | EP |
1 266-607 | Dec 2002 | EP |
1 266-607 | Dec 2002 | EP |
1 360-934 | Nov 2003 | EP |
1 360-934 | Nov 2003 | EP |
1 486-766 | Dec 2004 | EP |
1 486-766 | Dec 2004 | EP |
1 529-489 | May 2005 | EP |
1 529-489 | May 2005 | EP |
1 769-735 | Apr 2007 | EP |
63-305841 | Dec 1988 | JP |
3-63570 | Mar 1991 | JP |
03093189 | Apr 1991 | JP |
7-67861 | Mar 1995 | JP |
7-213925 | Aug 1995 | JP |
9-168530 | Jun 1997 | JP |
9-313465 | Sep 1997 | JP |
9-266889 | Oct 1997 | JP |
9-294737 | Nov 1997 | JP |
10-024028 | Jan 1998 | JP |
10-318970 | Dec 1998 | JP |
2000-126161 | May 2000 | JP |
2000-168754 | Jun 2000 | JP |
2000-254111 | Sep 2000 | JP |
2001-159618 | Jun 2001 | JP |
2001-305096 | Oct 2001 | JP |
2001-330581 | Nov 2001 | JP |
2002-502045 | Jan 2002 | JP |
2002-514453 | May 2002 | JP |
2003-180417 | Jul 2003 | JP |
2004-000598 | Jan 2004 | JP |
2004-500948 | Jan 2004 | JP |
2004-117339 | Apr 2004 | JP |
2004-522500 | Jul 2004 | JP |
2004-528936 | Sep 2004 | JP |
2005-503538 | Feb 2005 | JP |
2005-087613 | Apr 2005 | JP |
2006-512969 | Apr 2005 | JP |
2005-525149 | Aug 2005 | JP |
2005-237938 | Sep 2005 | JP |
2005-525846 | Sep 2005 | JP |
2005-527254 | Sep 2005 | JP |
2006-512974 | Apr 2006 | JP |
2006-516723 | Jul 2006 | JP |
2006-521555 | Sep 2006 | JP |
2006-527013 | Nov 2006 | JP |
2007-521031 | Aug 2007 | JP |
WO-9114212 | Sep 1991 | WO |
WO-9413203 | Jun 1994 | WO |
WO-9510223 | Apr 1995 | WO |
WO-9510223 | Apr 1995 | WO |
WO-9604857 | Feb 1996 | WO |
WO-9614026 | May 1996 | WO |
WO-9625088 | Aug 1996 | WO |
WO-9715227 | May 1997 | WO |
WO-9729847 | Aug 1997 | WO |
WO-9730344 | Aug 1997 | WO |
WO-9741421 | Nov 1997 | WO |
WO-9831275 | Jul 1998 | WO |
WO-9835225 | Aug 1998 | WO |
WO-9912008 | Mar 1999 | WO |
WO-9944508 | Sep 1999 | WO |
WO-9958051 | Nov 1999 | WO |
WO-0009184 | Feb 2000 | WO |
WO-0013573 | Mar 2000 | WO |
WO-0014269 | Mar 2000 | WO |
WO-0014535 | Mar 2000 | WO |
WO-0018449 | Apr 2000 | WO |
WO-0018449 | Apr 2000 | WO |
WO-0036400 | Jun 2000 | WO |
WO-0042422 | Jul 2000 | WO |
WO-0074763 | Dec 2000 | WO |
WO-0074763 | Dec 2000 | WO |
WO-0078208 | Dec 2000 | WO |
WO-0116575 | Mar 2001 | WO |
WO-0152727 | Jul 2001 | WO |
WO-0164105 | Sep 2001 | WO |
WO-0164105 | Sep 2001 | WO |
WO-0172220 | Oct 2001 | WO |
WO-0180728 | Nov 2001 | WO |
WO-0185233 | Nov 2001 | WO |
WO-0185233 | Nov 2001 | WO |
WO-0191634 | Dec 2001 | WO |
WO-0191634 | Dec 2001 | WO |
WO-0200101 | Jan 2002 | WO |
WO-0200101 | Jan 2002 | WO |
WO-0249507 | Jun 2002 | WO |
WO-0249509 | Jun 2002 | WO |
WO-0249509 | Jun 2002 | WO |
WO-02082052 | Oct 2002 | WO |
WO-02082052 | Oct 2002 | WO |
WO-02093144 | Nov 2002 | WO |
WO-02100251 | Dec 2002 | WO |
WO-02100251 | Dec 2002 | WO |
WO-02101359 | Dec 2002 | WO |
WO-02101359 | Dec 2002 | WO |
WO-03030984 | Apr 2003 | WO |
WO-03066128 | Aug 2003 | WO |
WO-03066128 | Aug 2003 | WO |
WO-03070099 | Aug 2003 | WO |
WO-03071940 | Sep 2003 | WO |
WO-03071940 | Sep 2003 | WO |
WO-2004062499 | Jul 2004 | WO |
WO-2004062500 | Jul 2004 | WO |
WO-2004062500 | Jul 2004 | WO |
WO-2004064636 | Aug 2004 | WO |
WO-2005006939 | Jan 2005 | WO |
WO-2005006939 | Jan 2005 | WO |
WO-2005009238 | Feb 2005 | WO |
WO-2005018709 | Mar 2005 | WO |
WO-2005018709 | Mar 2005 | WO |
WO-2005084546 | Sep 2005 | WO |
WO-2005084546 | Sep 2005 | WO |
WO-2005085995 | Sep 2005 | WO |
WO-2007041063 | Apr 2007 | WO |
WO-2007041063 | Apr 2007 | WO |
WO-2007041244 | Apr 2007 | WO |
WO-2007041244 | Apr 2007 | WO |
WO-2007041287 | Apr 2007 | WO |
WO-2007041287 | Apr 2007 | WO |
WO-2007041355 | Apr 2007 | WO |
WO-2007041355 | Apr 2007 | WO |
WO-2011065981 | Jun 2011 | WO |
Entry |
---|
Ada Consensus Development Panel. (Jan.-Feb. 1987). “Consensus Statement on Self-Monitoring of Blood Glucose,” Diabetes Care 10(1):95-99. |
Ada (Jan. 1994). “Self-Monitoring of Blood Glucose,” Consensus Statement Diabetes Care 17(1):81-86. |
Anonymous. (Sep. 30, 1993). “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus.” The New England Journal of Medicine 329(14):977-986. |
Anonymous. (Jun. 23, 1998). “Taking the “Ouch” Out of Needles: Arrays of “Microneedles” Offer New Techniques for Drug Delivery,” Science Daily, located at <http:www.sciencedaily.com/releases/1998/06/980623045850.htm>, last visited Jan. 14, 2014, 3 pages. |
Beregszàszi, M. et al. (Jul. 1997). “Nocturnal Hypoglycemia in Children and Adolescents with Insulin-Dependent Diabetes Mellitus: Prevalence and Risk Factors,” J. Pediatrics 131(1 Pt. 1):27-33. |
Chase, H.P. et al. (Feb. 2001). “Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes,” Pediatrics 107(2):222-226. |
Clarke, W.L. et al. (Sep.-Oct. 1987). “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose,” Diabetes Care 10(5):622-628. |
Collison, M.E. et al. (Sep. 1999). “Analytical Characterization of Electrochemical Biosensor Test Strips for Measurement of Glucose in Low-Volume Interstitial Fluid Samples,” Clinical Chemistry 45(9):1665-1673. |
Cox, D.J. et al. (Jun. 1997). “Understanding Error Grid Analysis,” Diabetes Care 20(6):911-912. |
D'Arrigo, T.D. (Mar. 2000). “GlucoWatch Monitor Poised for Approval,” Diabetes Forecast, 53(3):43-44. |
Feldman, B. et al. (2000). “FreeStyleI M: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing, Diabetes Technology and Therapeutics,” 2(2):221-229. |
International Search Report mailed Jan. 28, 2011, for PCT Application No. PCT/US2010/003063, filed on Nov. 30, 2010, 1 page. |
Johnson, R.N. et al. (Jan. 1998). “Accuracy of Devices Used for Self-Monitoring of Blood Glucose,” Annals of Clinical Biochemistry 35(1):68-74. |
Johnson, R.N. et al. (Jan. 1999). “Analytical Error of Home Glucose Monitors: A Comparison of 18 Systems,” Annals of Clinical Biochemistry 36(1):72-79. |
Johnson, R.N. et al. (2001). “Error Detection and Measurement in Glucose Monitors,” Clinica Chimica Acta 307:61-67. |
Kumetrix, Inc. (Dec. 1999). “Painless Blood Glucose Monitoring, Courtesy of the Mosquito,” Start-Up pp. 27-28. |
Lee, S-C. (Jun. 1999). “Light Scattering by Closely Spaced Parallel Cylinders Embedded in a Finite Dielectric Slab,” Journal of the Optical Society of America A 16(6):1350-1361. |
Mahler, R.J. et al. (1999). “Clinical Review 102, Type 2 Diabetes Melitus: Update on Diagnosis Pathophysiology, and Treatment,” The Journal of Clinical Endocrinology and Metabolism 84(4):1165-1171. |
McGarraugh, G. et al. (2001). “Physiological Influences on Off-Finger Glucose Testing,” Diabetes Technology & Therapeutics 3(3):367-376. |
McNichols, R.J. et al. (Jan. 2000). “Optical Glucose Sensing in Biological Fluids: An Overview,” Journal of Biomedical Optics, 5(1):5-16. |
Medline Plus. (Jun. 17, 2008). , Medical Encyclopedia, Monitor Blood Glucose-Series: Part 1-4, 6 pages. |
Neeley, W.E. et al. (1981). “An Instrument for Digital Matrix Photometry,” Clinical Chemistry 27(10):1665-1668. |
Neeley, W.E. (1983). “Reflectance Digital Matrix Photometry,” Clinical Chemistry 29(6):1038-1041. |
Neeley, W.E. (1983). “Multilayer Film Analysis for Glucose in 1- μL Samples of Plasma,” Clinical Chemistry 29(12):2103-2105. |
Neeley, W.E. (1988). “A Reflectance Photometer with a Square Photodiode Array Detector for Use on Multilayer Dry-Film Slides,” Clinical Chemistry 34(11):2367-2370. |
Otto, E. et al. (2000). “An Intelligent Diabetes Software Prototype: Predicting Blood Glucose Levels and Recommending Regimen Changes,” Diabetes Technology and Therapeutics 2(4):569-576. |
Pfohl, M. et al. (2000). “Spot Glucose Measurement in Epidermal Interstitial Fluid—An Alternative to Capillary Blood Glucose Estimation,” Experimental and Clinical Endocrinology & Diabetes 108(1):1-4. |
Princen, H.M. (May 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, I. Capillary Rise Between Two Cylinders,” Journal of Colloid and Interface Science 30(1):69-75. |
Princen, H.M. (Jul. 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, II. Capillary Rise in Systems with More Than Two Cylinders,” Journal of Colloid and Interface Science 30(3):359-371. |
Rebrin, K. et al. (Sep. 1999). “Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring,” American Journal of Physiology 277(3):E561-E571. |
Smart, W.H. et al. (2000). “The Use of Silicon Microfabrication Technology in Painless Glucose Monitoring, ”Diabetes Technology & Therapeutics 2(4):549-559. |
Svedman, C. et al. (Apr. 1999). “Skin Mini-Erosion Technique for Monitoring Metabolites in Interstitial Fluid: Its Feasibility Demonstrated by OGTT Results in Diabetic and Non-Diabetic Subjects,” Scand. J. Clin. Lab. Invest. 59(2):115-123. |
Trinder, P. (1969). “Determination of Glucose in Blood Using Glucose Oxidase with an Alternate Oxygen Acceptor,” Annals of Clinical Biochemistry 6:24-28. |
Written Opinion mailed Jan. 28, 2011, for PCT Application No. PCT/US2010/003063, filed on Nov. 30, 2010, 6 pages. |
Yum, S. I. et al. (Nov. 1, 1999). “Capillary Blood Sampling for Self-Monitoring of Blood Glucose,” Diabetes Technology & Therapeutics, 1(1):29-37. |
Number | Date | Country | |
---|---|---|---|
20110294152 A1 | Dec 2011 | US |
Number | Date | Country | |
---|---|---|---|
61358791 | Jun 2010 | US | |
61265247 | Nov 2009 | US |